tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Cell Encapsulation'

Nuvilex, Inc. Strengthens its Hand in the Cancer Arena with Purchase of Assets

Nuvilex, Inc. Strengthens its Hand in the Cancer Arena with Purchase of Assets

Written by ι Stock Market Media Group Staff — July 30, 2013

Nuvilex, Inc. (OTCQB: NVLX) became a much more valuable company in July when it closed a deal it was fully prepared to pay a great deal more money for, but while it spent far fewer dollars, the assets it purchased could prove to fetch a price tag exponentially greater than the $1.5 million the company paid.  In addition, Nuvilex originally set aside 100 million of its common shares to negotiate a ...

Read More →
0

Nuvilex, Inc. Moves Closer to Head to Head with Eli Lilly in Phase III Clinical Trials

Nuvilex, Inc. Moves Closer to Head to Head with Eli Lilly in Phase III Clinical Trials

Written by ι Stock Market Media Group Staff — July 25, 2013

Nuvilex, Inc. (OTCQB: NVLX) is currently preparing the way to challenge Eli Lilly’s (NYSE: LLY) blockbuster cancer drug, Gemzar, and doing so with the knowledge that in two independent mid-phase clinical trials, the company’s treatment involving its proprietary living cell encapsulation technology has outperformed the pharmaceutical giant.  Nuvilex has produced better results when compared to historical data for Gemzar, and now the company is ready to use real time, head to ...

Read More →
0

Nuvilex, Inc. Acquisition Could Be Steal of the Century and Worth Billions

Nuvilex, Inc. Acquisition Could Be Steal of the Century and Worth Billions

Written by ι Stock Market Media Group Staff — July 18, 2013

In a recently announced acquisition deal, Nuvilex, Inc. (OTCQB: NVLX), pulled off what can only be described as the steal of the century.  The company was able to secure a deal that allowed it to “cherry-pick” the exact piece of the pie Nuvilex wanted from another company.  And, what was the exact piece of the pie Nuvilex wanted – Bio Blue Bird AG (BBB) and more importantly, its worldwide licenses ...

Read More →
0

Nuvilex, Inc. Will Enter Phase III Trials with Advantages Using Cell Encapsulation

Nuvilex, Inc. Will Enter Phase III Trials with Advantages Using Cell Encapsulation

Written by ι Stock Market Media Staff — July 9, 2013

When Nuvilex, Inc. (OTCQB: NVLX) enters its pivotal Phase III clinical trial using its cell encapsulation technology combined with the anti-cancer drug ifosfamide for the treatment of late stage, inoperable pancreatic cancer, the company will do so with a number of distinct advantages.  The encapsulated cells capable of converting ifosfamide into its “cancer-killing” form could very well prove to be the “magic bullet” that catapults Nuvilex’s treatment to the standard therapy ...

Read More →
0

Nuvilex, Inc., Johnson & Johnson, and Medtronic, Inc., All Developing Type of “Artificial Pancreas” for Diabetics

Nuvilex, Inc., Johnson & Johnson, and Medtronic, Inc., All Developing Type of “Artificial Pancreas” for Diabetics

Written by ι Stock Market Media Group Staff — July 2, 2013

While Medtronic, Inc. (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are developing devices that can essentially act as a type of “artificial pancreas,” Nuvilex, Inc.’s (OTCQB: NVLX) unique cell encapsulation technology has shown it too can develop a type of “artificial pancreas” in preclinical diabetes studies.  Their approaches couldn’t be more different; however, all three companies are convinced that developing an artificial pancreas offers diabetics the best solution to ...

Read More →
0

Nuvilex, Inc. a Biotech Developing Treatments for Healthcare’s Hard Targets

Nuvilex, Inc. a Biotech Developing Treatments for Healthcare’s Hard Targets

Written by ι Stock Market Media Group Staff — June 26, 2013

Nuvilex, Inc. (OTCQB: NVLX) executives aren’t daunted by the statistics.  As a matter of fact, they’re aware the research they do is directed towards attacking what the company’s Chief Operations Officer, Dr. Gerald Crabtree, calls two of cancer’s “hard targets.”  “Pancreatic cancer and brain cancers represent two such targets.  Pancreatic cancer because it doesn’t present overt symptoms until the cancer is at an advanced stage; therefore, it is more difficult to ...

Read More →
0
Page 4 of 7 «...23456...»
ContactUs.com